N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in
neurocognitive dysfunction associated with schizophrenia. Further, several novel
glutamate-based classes of compound are presently in development as potential novel
treatments for persistent negative and cognitive symptoms. The study will assess
effectiveness of a NMDA-based intervention on biomarkers related to schizophrenia as a
mechanism for developing appropriate outcome batteries for future trials of novel compounds.